Novel methods of treating hearing loss
US-2024390323-A1 · Nov 28, 2024 · US
Chemical modulators of signaling pathways and therapeutic use
US10905665B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10905665-B2 |
| Application number | US-201615739390-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 24, 2016 |
| Priority date | Jun 24, 2015 |
| Publication date | Feb 2, 2021 |
| Grant date | Feb 2, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Described are methods of treating a disease associated with dysregulation of the Wnt/Frizzled signaling pathway. The methods include identifying subjects in need of therapy, administering inhibitors of the Wnt/Frizzled signaling pathway, pharmaceutical compositions including the inhibitors, and methods of using the compounds and compositions for treating cancer, bacterial and viral infection, lupus, type II diabetes, nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) in a subject.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound selected from the group consisting of: 4-chloro-2-((2-chloro-4-nitrophenyl)carbamoyl)phenyl octanoate; 4-chloro-2-((2-chloro-4-nitrophenyl)carbamoyl)phenyl oleate; 4-chloro-2-((2-chloro-4-nitrophenyl)carbamoyl)phenyl (9Z,12Z)-octadeca-9,12-dienoate; and 4-chloro-2-((2-chloro-4-nitrophenyl)carbamoyl)phenyl stearate, or a pharmaceutically acceptable salt thereof. 2. A pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title
- A61K31/167Primary
having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol · CPC title
Antineoplastic agents · CPC title
having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide · CPC title
Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10905665B2 cover?
- Described are methods of treating a disease associated with dysregulation of the Wnt/Frizzled signaling pathway. The methods include identifying subjects in need of therapy, administering inhibitors of the Wnt/Frizzled signaling pathway, pharmaceutical compositions including the inhibitors, and methods of using the compounds and compositions for treating cancer, bacterial and viral infection, l…
- Who is the assignee on this patent?
- Univ Duke
- What technology area does this patent fall under?
- Primary CPC classification A61K31/167. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).